Literature DB >> 21769668

Propofol protects against impairment of learning-memory and imbalance of hippocampal Glu/GABA induced by electroconvulsive shock in depressed rats.

Jie Luo1, Su Min, Ke Wei, Ping Li, Jun Dong, Yong-Feng Liu.   

Abstract

PURPOSE: General anesthetics are believed to induce amnesia. However, propofol can ameliorate cognitive deficits induced by electroconvulsive therapy (ECT), a treatment for mental disorders. This study aimed at investigating the possible molecular mechanism as well as the effects of propofol on learning-memory impairment in depressed rats induced by ECS (electroconvulsive shock, the analog of ECT to animals).
METHODS: Rats were treated with ECS (or sham ECS) pretreated with intraperitoneal injection of propofol (100 mg/kg) (or normal saline, 0.01 l/kg) after being treated with chronic unpredictable mild stresses to reproduce an animal model of depression. Sucrose preference test, open field test, and Morris water maze were used to assess behavioral changes. Hippocampal glutamate (Glu) and γ-aminobutyric acid (GABA) levels were measured with liquid chromatography, and glutamic acid decarboxylase 65 (GAD65) was assayed immunohistochemically. Additionally, rats undergoing ECS that were pretreated with pentobarbital sodium (45 mg/kg) were included for behavioral tests and electroencephalogram recording for comparison with rats undergoing ECS that were pretreated with propofol or normal saline.
RESULTS: ECS rats pretreated with propofol or pentobarbital sodium exhibited similar decreased seizure durations as compared with ECS rats pretreated with normal saline. ECS pretreated with normal saline aggravated learning-memory deficits whereas ECS pretreated with propofol or pentobarbital sodium did not. Rats undergoing ECS pretreated with propofol showed better memory than those undergoing ECS after pretreatment with pentobarbital sodium. ECS pretreated with normal saline downregulated the ratio of Glu/GABA and upregulated GAD65 expression; all these molecular changes were nearly normalized to the level of control group by ECS pretreated with propofol. There were no significant differences of depressive behaviors between groups treated with ECS.
CONCLUSIONS: The data suggest that propofol alleviated ECS-induced learning-memory impairment without interfering with the antidepressant efficacy of ECS, possibly by inhibiting excessive expression of GAD65 and maintaining the balance between glutamatergic and GABAergic amino acids neurotransmitters in the hippocampus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769668     DOI: 10.1007/s00540-011-1199-z

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  37 in total

1.  Effects of electroconvulsive therapy and propofol on spatial memory and glutamatergic system in hippocampus of depressed rats.

Authors:  Jun Dong; Su Min; Ke Wei; Ping Li; Jun Cao; Yan Li
Journal:  J ECT       Date:  2010-06       Impact factor: 3.635

Review 2.  Anesthesia management for electroconvulsive therapy: hemodynamic and respiratory management.

Authors:  Shigeru Saito
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

3.  A comparison of visual and computer-generated measures of "seizure quality".

Authors:  P B Rosenquist; W V McCall; C C Colenda; B A Melton
Journal:  J ECT       Date:  1998-06       Impact factor: 3.635

Review 4.  Anesthesia and memory processes.

Authors:  A Cherkin; P Harroun
Journal:  Anesthesiology       Date:  1971-05       Impact factor: 7.892

5.  Effects of intravenous anesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition.

Authors:  D J Buggy; B Nicol; D J Rowbotham; D G Lambert
Journal:  Anesthesiology       Date:  2000-04       Impact factor: 7.892

6.  Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness.

Authors:  Alexander Sartorius; Magdalena M Mahlstedt; Barbara Vollmayr; Fritz A Henn; Gabriele Ende
Journal:  Neuroreport       Date:  2007-09-17       Impact factor: 1.837

Review 7.  Blocking conversion of GABAergic inhibition as a potential mechanism of propofol-mediated brain protection following resuscitation.

Authors:  Hui Zhang; Xiaopeng Mei; Wei Wang; Xude Sun
Journal:  Drug News Perspect       Date:  2009-11

8.  Propofol interruption of ECT seizure to reduce side-effects: a pilot study.

Authors:  Ronald L Warnell; Conrad M Swartz; Alice Thomson
Journal:  Psychiatry Res       Date:  2009-11-05       Impact factor: 3.222

9.  The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy.

Authors:  M N Avramov; M M Husain; P F White
Journal:  Anesth Analg       Date:  1995-09       Impact factor: 5.108

10.  Propofol protects cultured rat hippocampal neurons against N-methyl-D-aspartate receptor-mediated glutamate toxicity.

Authors:  P Hans; V Bonhomme; J Collette; A Albert; G Moonen
Journal:  J Neurosurg Anesthesiol       Date:  1994-10       Impact factor: 3.956

View more
  19 in total

1.  The neurotoxicity induced by PM2.5 might be strongly related to changes of the hippocampal tissue structure and neurotransmitter levels.

Authors:  Qingzhao Li; Jiali Zheng; Sheng Xu; Jingshu Zhang; Yanhua Cao; Zhenlong Qin; Xiaoqin Liu; Chunyang Jiang
Journal:  Toxicol Res (Camb)       Date:  2018-07-31       Impact factor: 3.524

2.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Authors:  C Laurent; S Burnouf; B Ferry; V L Batalha; J E Coelho; Y Baqi; E Malik; E Mariciniak; S Parrot; A Van der Jeugd; E Faivre; V Flaten; C Ledent; R D'Hooge; N Sergeant; M Hamdane; S Humez; C E Müller; L V Lopes; L Buée; D Blum
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

3.  Propofol exerts hippocampal neuron protective effects via up-regulation of metallothionein-3.

Authors:  Jianguo He; Changshun Huang; Juan Jiang; Lanhai Lv
Journal:  Neurol Sci       Date:  2012-02-25       Impact factor: 3.307

4.  ACC Glu/GABA ratio is decreased in euthymic bipolar disorder I patients: possible in vivo neurometabolite explanation for mood stabilization.

Authors:  Estêvão Scotti-Muzzi; Thais Chile; Ricardo Moreno; Bruno Fraccini Pastorello; Cláudia da Costa Leite; Anke Henning; Maria Concepcion Garcia Otaduy; Homero Vallada; Márcio Gerhardt Soeiro-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-01-28       Impact factor: 5.270

5.  Arachidonic acid attenuates learning and memory dysfunction induced by repeated isoflurane anesthesia in rats.

Authors:  Chunjiang Li; Qingwei Wang; Lanlan Li; Yun Liu; Hongwei Diao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Efficacy of memoral herbal on prevention of electroconvulsive therapy-induced memory impairment in mood disorder patients (isfahan - iran 2011).

Authors:  Seyed Ghafur Mousavi; Ghasemi Mohsen; Maracy M Reza; Ebrahimi Amrollah; Barekatain Majid; Noori Fariba
Journal:  Int J Prev Med       Date:  2012-07

7.  Comparison of the neuropsychological mechanisms of 2,6-diisopropylphenol and N-methyl-D-aspartate receptor antagonist against electroconvulsive therapy-induced learning and memory impairment in depressed rats.

Authors:  Gang Liu; Chao Liu; Xue-Ning Zhang
Journal:  Mol Med Rep       Date:  2015-05-21       Impact factor: 2.952

8.  Osthole improves synaptic plasticity in the hippocampus and cognitive function of Alzheimer's disease rats via regulating glutamate.

Authors:  Xiaohua Dong; Danshen Zhang; Li Zhang; Wei Li; Xianyong Meng
Journal:  Neural Regen Res       Date:  2012-10-25       Impact factor: 5.135

9.  Electroconvulsive Treatment: Hypotheses about Mechanisms of Action.

Authors:  Roar Fosse; John Read
Journal:  Front Psychiatry       Date:  2013-08-27       Impact factor: 4.157

10.  Orchestrated regulation of Nogo receptors, LOTUS, AMPA receptors and BDNF in an ECT model suggests opening and closure of a window of synaptic plasticity.

Authors:  Max Nordgren; Tobias Karlsson; Maria Svensson; Josefin Koczy; Anna Josephson; Lars Olson; Anders Tingström; Stefan Brené
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.